文献速递骨质疏松与代谢性骨病

在常规临床实践中,骨密度监测的首选部位是哪个部位可作为治疗相关抗骨折效果的指标?一项基于登记数据的队列研究

Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
PubMed 文献 · Osteoporos Int · 2019-04-23

该研究基于加拿大曼尼托巴省人群骨密度登记数据,纳入6093名年龄>40岁、启动骨质疏松治疗且接受两次连续双能X线吸收检测(DXA)的女性(平均间隔4.7年),比较脊柱与全髋骨密度变化作为治疗相关骨折风险降低指标的价值。平均随访12.1年,995例发生主要骨质疏松性骨折。全髋骨密度可检测性降低与主要骨质疏松性骨折风险升高相关(aHR 1.46,95%CI 1.25-1.70),可检测性升高与风险降低相关(aHR 0.71,95%CI 0.61-0.83);脊柱骨密度变化与骨折风险无独立关联。

要点

  • 全髋骨密度可检测性降低者主要骨质疏松性骨折风险升高(aHR 1.46,95%CI 1.25-1.70)。
  • 全髋骨密度可检测性升高者主要骨质疏松性骨折风险降低(aHR 0.71,95%CI 0.61-0.83)。
  • 脊柱骨密度变化与骨折风险无独立关联。

核心结论

  • 治疗相关全髋骨密度升高与主要骨质疏松性骨折、髋部骨折及临床椎体骨折风险降低相关,而骨密度降低与骨折风险升高相关。
  • 相比之下,脊柱骨密度变化与骨折风险无独立关联。

研究设计与样本

  • 基于加拿大曼尼托巴省人群骨密度登记数据的队列研究。
  • 研究队列纳入6093名年龄>40岁、启动骨质疏松治疗且接受两次连续双能X线吸收检测(DXA)扫描的女性,平均间隔4.7年。
  • 计算首次与第二次DXA扫描间脊柱、全髋和股骨颈骨密度变化,作为分类变量(稳定、可检测性降低或可检测性升高)和连续变量。
  • 使用Cox回归模型分析至首次 incident 骨折的时间,校正基线骨折概率,骨折事件从健康服务数据中确认。

主要发现

  • 平均随访12.1年期间,995名女性发生主要骨质疏松性骨折(MOF),包括246例髋部骨折和301例临床椎体骨折。
  • 与骨密度稳定相比,全髋骨密度可检测性降低者主要骨质疏松性骨折风险升高(aHR 1.46,95%CI 1.25-1.70)。
  • 与骨密度稳定相比,全髋骨密度可检测性升高者主要骨质疏松性骨折风险降低(aHR 0.71,95%CI 0.61-0.83)。
  • 校正脊柱骨密度变化后,上述结果未减弱。
  • 髋部骨折和临床椎体骨折结局、骨密度变化作为连续变量评估以及使用股骨颈骨密度监测替代全髋骨密度监测时,均观察到类似结果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Change in total hip bone mineral density (BMD) provides a robust indication of anti-fracture effect during treatment monitoring in routine clinical practice, whereas spine BMD change is not independently associated with fracture risk. PURPOSE: The role of monitoring bone mineral density (BMD) as an indicator of an anti-fracture effect is controversial. Discordance between the spine and hip BMD is common and creates uncertainty in clinical practice. METHODS: Using a population-based BMD Registry for the Province of Manitoba, Canada, we compared change in the spine and hip BMD as an indicator of treatment-related fracture risk reduction. The study cohort included 6093 women age > 40 years initiating osteoporosis treatment with two consecutive dual-energy X-ray absorptiometry (DXA) scans (mean interval 4.7 years). We computed change in the spine, total hip, and femur neck BMD between the first and second DXA scans as categorical (categorized as stable, detectable decrease, or detectable increase) and continuous measures. We modeled time to first incident fracture, ascertained from health services data, using Cox regression adjusted for baseline fracture probability. RESULTS: During a mean follow-up of 12.1 years, 995 women developed incident major osteoporotic fractures (MOF) including 246 with hip fractures and 301 with clinical vertebral fractures. Women with a detectable decrease in total hip BMD compared with stable BMD experienced an increase in MOF (adjusted hazard ratio [aHR] 1.46, 95% confidence interval [CI] 1.25-1.70) while those with a detectable increase in total hip BMD experienced a decrease in MOF (aHR 0.71, 95% CI 0.61-0.83), and these results were not attenuated when adjusted for change in spine BMD. Similar results were seen for hip and clinical vertebral fracture outcomes, when BMD change was assessed as a continuous measure, and when femur neck BMD monitoring was used instead of total hip BMD monitoring. CONCLUSIONS: Treatment-related increases in total hip BMD are associated with lower MOF, hip, and clinical vertebral fracture risk compared with stable BMD, while BMD decreases are associated with higher fracture risk. In contrast, spine BMD change is not independently associated with fracture risk.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Leslie WD, Martineau P, Bryanton M, et al. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study. Osteoporos Int. 2019. PMID: 31016351. doi:10.1007/s00198-019-04975-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。